KALA BIO, Inc. vs Kairos Pharma, Ltd. — Valuation Comparison 2026
Access all valuation models for KALA vs KAPA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →KAPA scores higher with a 4.6/10 quality rating vs KALA's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing KALA BIO, Inc. (KALA) and Kairos Pharma, Ltd. (KAPA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
KALA currently trades at $2.29 with a QOC of 3.4/10, while KAPA trades at $0.53 with a QOC of 4.6/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).